| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| AIDS Vaccines | 30 | 2024 | 152 | 8.250 |
Why?
|
| HIV Infections | 45 | 2024 | 5097 | 3.540 |
Why?
|
| HIV-1 | 20 | 2024 | 1260 | 2.480 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2021 | 196 | 1.730 |
Why?
|
| Adult | 39 | 2024 | 5913 | 1.230 |
Why?
|
| Humans | 57 | 2024 | 14537 | 1.210 |
Why?
|
| Young Adult | 31 | 2024 | 2498 | 1.180 |
Why?
|
| HIV Antibodies | 12 | 2024 | 247 | 1.090 |
Why?
|
| Female | 43 | 2024 | 9103 | 1.060 |
Why?
|
| Male | 36 | 2024 | 6754 | 1.060 |
Why?
|
| South Africa | 38 | 2023 | 7596 | 1.050 |
Why?
|
| Immunoglobulin G | 6 | 2024 | 231 | 0.970 |
Why?
|
| Altitude | 1 | 2024 | 9 | 0.930 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2024 | 19 | 0.930 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2024 | 151 | 0.930 |
Why?
|
| Anti-HIV Agents | 4 | 2021 | 1324 | 0.870 |
Why?
|
| Adolescent | 24 | 2024 | 2985 | 0.870 |
Why?
|
| Circumcision, Male | 3 | 2019 | 99 | 0.840 |
Why?
|
| Antibodies, Neutralizing | 5 | 2023 | 303 | 0.830 |
Why?
|
| Immunization, Secondary | 4 | 2021 | 72 | 0.780 |
Why?
|
| Double-Blind Method | 12 | 2024 | 272 | 0.750 |
Why?
|
| Contraception Behavior | 4 | 2011 | 54 | 0.750 |
Why?
|
| Neutropenia | 1 | 2021 | 9 | 0.740 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 8 | 0.730 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2020 | 10 | 0.690 |
Why?
|
| Condoms | 5 | 2020 | 88 | 0.540 |
Why?
|
| Sexual Behavior | 8 | 2023 | 320 | 0.520 |
Why?
|
| Adjuvants, Immunologic | 4 | 2024 | 23 | 0.510 |
Why?
|
| Polysorbates | 4 | 2024 | 10 | 0.510 |
Why?
|
| Squalene | 4 | 2024 | 10 | 0.510 |
Why?
|
| HIV Envelope Protein gp120 | 5 | 2024 | 104 | 0.480 |
Why?
|
| Genitalia | 1 | 2014 | 8 | 0.480 |
Why?
|
| Cell Phone | 3 | 2020 | 34 | 0.480 |
Why?
|
| Mucous Membrane | 1 | 2014 | 12 | 0.480 |
Why?
|
| Risk Factors | 6 | 2024 | 1475 | 0.470 |
Why?
|
| Specimen Handling | 1 | 2014 | 105 | 0.450 |
Why?
|
| Immunogenicity, Vaccine | 4 | 2024 | 103 | 0.450 |
Why?
|
| HIV Seropositivity | 3 | 2023 | 265 | 0.420 |
Why?
|
| Fertility | 2 | 2011 | 22 | 0.410 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2017 | 472 | 0.400 |
Why?
|
| Middle Aged | 10 | 2024 | 3601 | 0.380 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2012 | 472 | 0.370 |
Why?
|
| Menstruation | 2 | 2011 | 10 | 0.370 |
Why?
|
| Antibodies, Monoclonal | 3 | 2021 | 142 | 0.360 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 112 | 0.350 |
Why?
|
| Vaccination | 7 | 2020 | 365 | 0.350 |
Why?
|
| Menstruation Disturbances | 1 | 2010 | 7 | 0.340 |
Why?
|
| Mothers | 1 | 2012 | 195 | 0.340 |
Why?
|
| Intention | 2 | 2010 | 23 | 0.340 |
Why?
|
| Genetic Vectors | 7 | 2021 | 55 | 0.340 |
Why?
|
| Patient Preference | 1 | 2010 | 30 | 0.340 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2012 | 529 | 0.330 |
Why?
|
| Antibody Formation | 5 | 2020 | 61 | 0.330 |
Why?
|
| Decision Making | 1 | 2009 | 53 | 0.310 |
Why?
|
| Anti-Retroviral Agents | 2 | 2016 | 551 | 0.310 |
Why?
|
| Healthy Volunteers | 3 | 2024 | 18 | 0.300 |
Why?
|
| Focus Groups | 4 | 2020 | 196 | 0.280 |
Why?
|
| Incidence | 4 | 2022 | 685 | 0.260 |
Why?
|
| Self Report | 4 | 2020 | 114 | 0.260 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 3 | 2021 | 36 | 0.250 |
Why?
|
| Air Travel | 1 | 2024 | 4 | 0.240 |
Why?
|
| Oximetry | 1 | 2024 | 6 | 0.240 |
Why?
|
| Thrombelastography | 1 | 2024 | 6 | 0.240 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 6 | 0.230 |
Why?
|
| von Willebrand Factor | 1 | 2024 | 21 | 0.230 |
Why?
|
| Alum Compounds | 1 | 2024 | 1 | 0.230 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 20 | 0.230 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 29 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 293 | 0.230 |
Why?
|
| Thrombosis | 1 | 2024 | 47 | 0.230 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 370 | 0.220 |
Why?
|
| Data Accuracy | 1 | 2023 | 9 | 0.220 |
Why?
|
| Immunization, Passive | 2 | 2020 | 17 | 0.210 |
Why?
|
| Adenoviridae | 4 | 2018 | 39 | 0.210 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 29 | 0.210 |
Why?
|
| Vaginosis, Bacterial | 2 | 2019 | 19 | 0.210 |
Why?
|
| Treatment Outcome | 3 | 2020 | 889 | 0.200 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 101 | 0.200 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2022 | 2 | 0.200 |
Why?
|
| Glucosylceramidase | 1 | 2022 | 3 | 0.200 |
Why?
|
| Gaucher Disease | 1 | 2022 | 4 | 0.200 |
Why?
|
| Vagina | 2 | 2019 | 91 | 0.200 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 284 | 0.200 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 187 | 0.190 |
Why?
|
| Health Services Research | 1 | 2021 | 58 | 0.190 |
Why?
|
| Immunity, Innate | 1 | 2021 | 10 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2015 | 256 | 0.180 |
Why?
|
| Pandemics | 1 | 2023 | 296 | 0.180 |
Why?
|
| Culture | 2 | 2011 | 23 | 0.180 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 34 | 0.180 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 41 | 0.180 |
Why?
|
| HIV | 3 | 2022 | 380 | 0.180 |
Why?
|
| Socioeconomic Factors | 5 | 2015 | 411 | 0.180 |
Why?
|
| Injection Site Reaction | 1 | 2020 | 3 | 0.170 |
Why?
|
| Reminder Systems | 1 | 2020 | 8 | 0.170 |
Why?
|
| Arthralgia | 1 | 2020 | 4 | 0.170 |
Why?
|
| Headache | 1 | 2020 | 7 | 0.170 |
Why?
|
| Injections, Intramuscular | 1 | 2020 | 31 | 0.170 |
Why?
|
| Sex Factors | 1 | 2021 | 227 | 0.170 |
Why?
|
| Qualitative Research | 3 | 2012 | 321 | 0.170 |
Why?
|
| Contraception | 2 | 2011 | 90 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2012 | 262 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2019 | 1 | 0.170 |
Why?
|
| Administration, Intravaginal | 1 | 2019 | 50 | 0.170 |
Why?
|
| Lactobacillus | 1 | 2019 | 7 | 0.170 |
Why?
|
| Probiotics | 1 | 2019 | 12 | 0.170 |
Why?
|
| Survival Rate | 1 | 2019 | 96 | 0.170 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 52 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 244 | 0.160 |
Why?
|
| Virion | 1 | 2019 | 12 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2019 | 49 | 0.160 |
Why?
|
| Vaccines, DNA | 2 | 2016 | 11 | 0.160 |
Why?
|
| Vaginal Smears | 1 | 2019 | 34 | 0.160 |
Why?
|
| HIV Antigens | 4 | 2021 | 26 | 0.160 |
Why?
|
| Reproductive Tract Infections | 1 | 2018 | 8 | 0.160 |
Why?
|
| Cross-Sectional Studies | 5 | 2017 | 1422 | 0.150 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 563 | 0.150 |
Why?
|
| Adolescent Behavior | 2 | 2015 | 60 | 0.150 |
Why?
|
| Pregnancy | 4 | 2012 | 1862 | 0.150 |
Why?
|
| Risk-Taking | 4 | 2020 | 121 | 0.150 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2018 | 103 | 0.140 |
Why?
|
| Immunity, Humoral | 4 | 2019 | 42 | 0.140 |
Why?
|
| Pleural Cavity | 1 | 2017 | 7 | 0.140 |
Why?
|
| Radiography | 1 | 2017 | 80 | 0.140 |
Why?
|
| Genital Diseases, Male | 1 | 2016 | 8 | 0.130 |
Why?
|
| Penis | 1 | 2016 | 8 | 0.130 |
Why?
|
| Foreskin | 1 | 2016 | 12 | 0.130 |
Why?
|
| Sexual Partners | 3 | 2015 | 215 | 0.130 |
Why?
|
| Tuberculosis Vaccines | 1 | 2015 | 8 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2017 | 195 | 0.120 |
Why?
|
| Interviews as Topic | 3 | 2011 | 203 | 0.120 |
Why?
|
| Coinfection | 1 | 2017 | 276 | 0.120 |
Why?
|
| Violence | 1 | 2015 | 68 | 0.120 |
Why?
|
| Viral Vaccines | 2 | 2024 | 24 | 0.120 |
Why?
|
| Protein Precursors | 1 | 2014 | 22 | 0.110 |
Why?
|
| Poverty | 1 | 2015 | 152 | 0.110 |
Why?
|
| Reproductive Health Services | 1 | 2015 | 66 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2013 | 22 | 0.110 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2017 | 324 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2011 | 120 | 0.110 |
Why?
|
| Floxacillin | 1 | 2013 | 6 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 13 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2015 | 240 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2020 | 225 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 280 | 0.100 |
Why?
|
| Prejudice | 1 | 2012 | 8 | 0.100 |
Why?
|
| Maternal Health Services | 1 | 2012 | 52 | 0.090 |
Why?
|
| Canarypox virus | 2 | 2021 | 4 | 0.090 |
Why?
|
| Africa South of the Sahara | 3 | 2021 | 353 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2021 | 175 | 0.090 |
Why?
|
| Reproductive Behavior | 1 | 2010 | 3 | 0.090 |
Why?
|
| Amenorrhea | 1 | 2010 | 9 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2019 | 967 | 0.090 |
Why?
|
| Vaccines, Synthetic | 2 | 2024 | 12 | 0.090 |
Why?
|
| Viremia | 1 | 2010 | 66 | 0.090 |
Why?
|
| Treatment Refusal | 1 | 2010 | 13 | 0.090 |
Why?
|
| Contraceptive Agents, Female | 1 | 2010 | 47 | 0.080 |
Why?
|
| Women's Health | 1 | 2009 | 41 | 0.080 |
Why?
|
| Safe Sex | 2 | 2019 | 68 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 125 | 0.080 |
Why?
|
| Papillomaviridae | 1 | 2008 | 34 | 0.080 |
Why?
|
| Drug Resistance, Viral | 1 | 2010 | 278 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2008 | 165 | 0.070 |
Why?
|
| Risk | 2 | 2021 | 87 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2008 | 74 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2019 | 39 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2017 | 656 | 0.070 |
Why?
|
| Immunity, Cellular | 2 | 2018 | 25 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2012 | 1479 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2019 | 1160 | 0.060 |
Why?
|
| Genotype | 2 | 2022 | 442 | 0.060 |
Why?
|
| Substance-Related Disorders | 2 | 2015 | 51 | 0.060 |
Why?
|
| Tetanus Toxoid | 1 | 2024 | 14 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 163 | 0.060 |
Why?
|
| Hepatitis B Vaccines | 1 | 2024 | 40 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2024 | 34 | 0.060 |
Why?
|
| Immunoglobulin A | 1 | 2024 | 39 | 0.060 |
Why?
|
| Disease Progression | 2 | 2017 | 154 | 0.050 |
Why?
|
| Child | 2 | 2022 | 2242 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 52 | 0.050 |
Why?
|
| Infant | 2 | 2022 | 2244 | 0.050 |
Why?
|
| Demography | 2 | 2014 | 105 | 0.050 |
Why?
|
| Community Participation | 1 | 2022 | 42 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 171 | 0.050 |
Why?
|
| Splenectomy | 1 | 2022 | 3 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 11 | 0.050 |
Why?
|
| Anemia | 1 | 2022 | 41 | 0.050 |
Why?
|
| Registries | 1 | 2022 | 91 | 0.050 |
Why?
|
| Americas | 1 | 2021 | 10 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 13 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 56 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 60 | 0.050 |
Why?
|
| Vaccinia virus | 1 | 2020 | 2 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2020 | 7 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 22 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 435 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 83 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2020 | 33 | 0.040 |
Why?
|
| Plasmids | 1 | 2020 | 23 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2013 | 799 | 0.040 |
Why?
|
| DNA | 1 | 2020 | 73 | 0.040 |
Why?
|
| Granzymes | 1 | 2019 | 1 | 0.040 |
Why?
|
| Text Messaging | 1 | 2020 | 25 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2020 | 30 | 0.040 |
Why?
|
| Cefixime | 1 | 2019 | 2 | 0.040 |
Why?
|
| Doxycycline | 1 | 2019 | 3 | 0.040 |
Why?
|
| Metronidazole | 1 | 2019 | 4 | 0.040 |
Why?
|
| CD40 Ligand | 1 | 2019 | 4 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2019 | 22 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2019 | 15 | 0.040 |
Why?
|
| Thailand | 1 | 2019 | 26 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 20 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 44 | 0.040 |
Why?
|
| Glycogen | 1 | 2019 | 3 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 97 | 0.040 |
Why?
|
| Coitus | 1 | 2019 | 15 | 0.040 |
Why?
|
| Viral Load | 2 | 2016 | 819 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 65 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2019 | 108 | 0.040 |
Why?
|
| Unsafe Sex | 1 | 2019 | 46 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 179 | 0.040 |
Why?
|
| Trichomonas Vaginitis | 1 | 2018 | 4 | 0.040 |
Why?
|
| Trichomonas Infections | 1 | 2018 | 5 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 2018 | 7 | 0.040 |
Why?
|
| Syphilis | 1 | 2018 | 14 | 0.040 |
Why?
|
| Chlamydia Infections | 1 | 2018 | 17 | 0.040 |
Why?
|
| Gonorrhea | 1 | 2018 | 20 | 0.040 |
Why?
|
| Candidiasis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Dizziness | 1 | 2018 | 2 | 0.040 |
Why?
|
| Back Pain | 1 | 2018 | 4 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2018 | 14 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 10 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2018 | 7 | 0.040 |
Why?
|
| Africa, Southern | 1 | 2018 | 91 | 0.040 |
Why?
|
| Fatigue | 1 | 2018 | 20 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 125 | 0.040 |
Why?
|
| Data Collection | 1 | 2018 | 86 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2018 | 101 | 0.040 |
Why?
|
| Diarrhea | 1 | 2018 | 76 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2022 | 1748 | 0.030 |
Why?
|
| Aged | 1 | 2022 | 1740 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2017 | 47 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 188 | 0.030 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2016 | 2 | 0.030 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2016 | 16 | 0.030 |
Why?
|
| Africa, Eastern | 1 | 2016 | 17 | 0.030 |
Why?
|
| Pediatrics | 1 | 2016 | 17 | 0.030 |
Why?
|
| United States | 1 | 2016 | 132 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 150 | 0.030 |
Why?
|
| Acyltransferases | 1 | 2015 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2015 | 11 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 2015 | 20 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2015 | 32 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 48 | 0.030 |
Why?
|
| Sex Offenses | 1 | 2015 | 29 | 0.030 |
Why?
|
| Animals | 1 | 2018 | 1081 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2014 | 10 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2015 | 153 | 0.030 |
Why?
|
| Depression | 1 | 2015 | 121 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 127 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2011 | 16 | 0.020 |
Why?
|
| Brazil | 1 | 2011 | 47 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 106 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 25 | 0.020 |
Why?
|
| Kenya | 1 | 2011 | 183 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 254 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2015 | 543 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 1192 | 0.020 |
Why?
|